Astria Therapeutics
ATXS
About: Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Employees: 78
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
42% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 31
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
0% less capital invested
Capital invested by funds: $311M [Q1] → $310M (-$1.55M) [Q2]
1.37% less ownership
Funds ownership: 103.35% [Q1] → 101.98% (-1.37%) [Q2]
8% less funds holding
Funds holding: 115 [Q1] → 106 (-9) [Q2]
39% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 23
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
HC Wainwright & Co.
Joseph Pantginis
|
$20
|
Buy
Maintained
|
17 Sep 2025 |
|
Cantor Fitzgerald
Steven Seedhouse
|
$49
|
Overweight
Reiterated
|
17 Sep 2025 |
|
JMP Securities
Jonathan Wolleben
|
$26
|
Market Outperform
Maintained
|
13 Aug 2025 |
Financial journalist opinion
Based on 8 articles about ATXS published over the past 30 days
